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Context: The individual variability in thewaning androgenic-anabolic functions of agingmenmay
be influenced by the CAG repeat polymorphism in exon 1 of the androgen receptor (AR), affecting
androgen sensitivity. However, findings on its phenotypic effects are inconclusive.
Objective:Theaimwas to investigate the relationshipsbetweenhealth status, various reproductive
hormones, and the AR CAG repeat length.
Design:Weconducted amultinational prospective cohort observational studywith cross-sectional
baseline data.
Setting: This was a population survey of community-dwelling men.
Participants:Men (40–79 yr old; n3369)were randomly recruited fromcenters in eight European
countries; CAG repeat analysis was performed in 2878 men.
Main Outcome Measures:We measured the correlations of the CAG repeat length with selected
endocrine, metabolic, and phenotypic parameters related to aging and sex hormone action.
Results:Onlyminordifferenceswere found inCAG repeat lengths between theeight European coun-
tries. They showed significant positive association with total, free, and bioavailable levels of testos-
terone (T) and estradiol. FSH but not LH correlated inversely with CAG repeat length. Significant
associationswere foundwith bone ultrasound parameters at the calcaneus. Negative correlationwas
found with triglycerides, but not with other blood lipids or with anthropometry, blood pressure,
hemoglobin, insulin sensitivity, or sexual and prostatic functions.
Conclusions: TheARCAG repeat length correlates significantlywith serumTandestradiol of aging
men. Weaker transcriptional activity of the AR with longer CAG-encoded polyglutamine repeats
appears to be totally or nearly totally compensated for by higher T levels. The residual phenotypic
correlations may reflect differences in estrogen levels/actions after aromatization of the higher T
levels. (J Clin Endocrinol Metab 94: 277–284, 2009)
O R I G I N A L A R T I C L E
E n d o c r i n e R e s e a r c h
J Clin Endocrinol Metab, January 2009, 94(1):277–284 jcem.endojournals.org 277
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 09 February 2015. at 01:56 For personal use only. No other uses without permission. . All rights reserved.
Since the original discovery that the length of the CAG repeatpolymorphism in exon 1 of the androgen receptor (AR)
correlates inversely with the strength of androgen action, its as-
sociations with phenotypic variations in androgen action have
been studied extensively (1). Shorter repeats with stronger an-
drogen action have been associated, for example, with increased
risk of prostate cancer, adverse plasma lipid profile, and male-
type alopecia. Longer repeats withweaker androgen action have
been associated with impaired spermatogenesis. Extreme repeat
lengths (40) cause spinobulbar muscular atrophy (Kennedy’s
syndrome), including a variable degree of androgen insensitivity.
When the hypothalamic-pituitary-gonadal axis functions
normally, one could expect that the diminished testosterone (T)
feedback associated with weakened AR activity would be com-
pensated for by increased LH-stimulated androgen production.
We could hypothesize that the compensation is incomplete if
signs of androgen deficiency occur with longer CAG repeats.
However, closer scrutiny of existing data does not reveal definite
signs of androgen deficiency in men with longer repeats (1, 2).
Several (2, 3), but not all (4–7), studies have shown that theCAG
repeat length directly correlates with serum T levels, indicating
that the weaker AR activity may indeed be compensated for by
higher androgen levels. In addition, some (2, 7), but not all (5, 6),
studies have documented concurrent increases in estrogen levels.
The discrepant findings on CAG repeat vs. sex hormone levels
are at least partly due to small sample sizes, but different genetic
backgrounds and modifying inputs between populations may
also contribute to the variability. The functional importance of
the enhanced estrogen production and altered androgen/estro-
gen balancewith increasedCAGrepeat lengths has received little
attention. Pointers to its importance do exist, such as gynecom-
astia (8, 9) and reduced risk for male-type alopecia (10) in pa-
tients with Kennedy’s syndrome. However, most studies have in-
terpreted the phenotypic effects of long CAG repeats to be caused
byandrogendeficiency.Usingobservationsof theuniqueEuropean
Male Ageing Study, comprisingARCAG repeat lengths and endo-
crineandclinicalcharacteristicsofnearly3000men,aged40–79yr,
we provide evidence that the direct correlation of the AR CAG
repeat length with estrogen, rather than T, may be important in
determining the phenotypic effects of this polymorphism.
Subjects and Methods
Study population
The European Male Ageing Study (EMAS), as described elsewhere
(11–13), is a European Union-funded multicenter, prospective, popula-
tion-based study of determinants of male aging. The eight participating
centers are: Florence (Italy), Leuven (Belgium), Lodz (Poland), Malmo¨
(Sweden), Manchester (United Kingdom), Santiago de Compostela
(Spain), Szeged (Hungary), and Tartu (Estonia). We present here data
from the first phase of the study, a cross-sectional survey of a random
population sample of men aged 40–79 yr, completed in 2003–2005.
Ethics approval for the study was obtained in each center according to
local requirements. The number of men recruited ranged from 396 to 451
per center (total n 3369). DNA extraction and CAG repeat analysis was
carried out on 294 to 407 samples per center (total n 2878). There was
no difference in age, demographics, hormone, or bone ultrasound findings
between men with DNA available and unavailable (data not shown).
Blood sampling and processing
A single morning sample of fasting venous blood (before 1000 h),
processed and stored according to standard protocols, was used for the
DNA, hormone, hematological, and biochemical measurements. DNA
was extracted from leukocytes using standard phenol:chloroform ex-
traction after differential lysis of erythrocytes. Purified DNA was pre-
cipitated and stored at 80 C until analyzed.
CAG repeat determination
Genotyping of the CAG repeat was carried out in the laboratory of the
Centre for Integrated Genomic Medical Research (The University of
Manchester), using fluorescently-labeled PCR. Ten nanograms of DNA
were amplified in 10-l reactions containing 2.5 pmol each of fluorescently
labeled forward and reverse primer, 10 PCR buffer, 1.5 mMMgCl2, 0.2
mM dNTPs, and 0.2 U TaqDNA polymerase. The primer sequences were:
forward, 5-TCC AGA ATC TGT TCC AGA GCG TGC-3; and reverse,
5-GCT GTG AAGGTT GCT GTT CCT CAT-3. Reactions were cycled
at 95C for 5min; 10 cycles of 94C for 10 sec, 55C for 30 sec, and 72C for
30 sec; 20 cycles of 89C for 20 sec, 55C for 30 sec, and72C for 30 sec; and
finally, 72 C for 10 min. Samples were then run on an ABIPRISM 3100
Genetic Analyser (Applied Biosystems, Foster City, CA) and genotyped us-
ing Genescan (Applied Biosystems). Allele frequencies were checked for
consistency with HapMap data or literature where possible.
Hormone assays
The serum samples were transported in frozen state to the General
Laboratory, Azienda Ospedaliero-Universitaria Careggi (Florence,
Italy),where theywere assayed forT, estradiol (E2), FSH,LH,andSHBG
by the Modular E170 platform electrochemiluminescence immunoas-
says (Roche Diagnostics, Mannheim, Germany) as described previously
(13). Free T and E2 levels were derived from total hormone, SHBG, and
albumin concentrations (14). The details of assay performance and qual-
ity control have been presented before (Refs. 11 and 13; also see sup-
plementary material, published as supplemental data on The Endocrine
Society’s Journals Online web site at http://jcem.endojournals.org).
Anthropometric parameters
Body weight, height, body mass index (BMI), and body circumfer-
ences (waist, hip, midcalf, and mid-upper arm) were measured as de-
scribed before (11). Percentage of body fat was calculated from total
body density (15).
Quantitative ultrasound (QUS)
All subjects had ultrasound assessment of the nondominant calca-
neus using a Sahara Clinical Sonometer (Hologic, Bedford, MA). Mea-
sured parameters included the velocity of ultrasound transmission
through bone [speed of sound (SOS) inmeters per second from the sound
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propagation time between the transducers] and the rate of loss of ultra-
sonic intensity with frequency [broadband ultrasound attenuation
(BUA) in decibels per megahertz using Fourier transformation of the
recorded signal]. Additional machine-derived parameters were QUS-es-
timated bone density in grams per square centimeter [bone mineral den-
sity (BMD)0.002592 (BUA SOS)3.687] andQUS index (QUI),
a measure of stiffness [QUI 0.41 (SOS) 0.41 (BUA) 571]. Short-
termprecision of themethodwas established onduplicatemeasurements
performed in20 randomly selected cohortmembers in theLeuven center.
The in vivo coefficients of variationwere2.8 and0.3%forBUAandSOS,
respectively, and 2.3 and 3.4% for QUI and QUS-estimated bone den-
sity, respectively. Further technical details about theBMDmeasurements
and their quality control are presented elsewhere (11).
Blood hematology, biochemistry, and lipids
A number of routine hematological and biochemical markers of gen-
eral health were measured using standardized methods under good lab-
oratory practice conditions in internationally and/or nationally accred-
ited hospital laboratories in each of the centers (11). Hematology
analyses included hemoglobin, and platelet, and red and white cell
counts. Biochemical measurements included glucose, albumin, choles-
terol, high-density lipoprotein (HDL) cholesterol, triglycerides, and low-
density lipoprotein (LDL) cholesterol (calculated from total and HDL
cholesterol, and fasting triglycerides using the Friedewald equation (16).
Parameters of insulin sensitivity
Insulin was measured in a single laboratory (Complejo Hospitalario
Universitario de Santiago, Santiago de Compostela, Spain) using a spe-
cific ELISA assay (17). Insulin resistance, sensitivity, and pancreatic
-cell function were estimated according to the homeostasis model as-
sessment (HOMA-IR, HOMA-S, and HOMA-B, respectively) (18). In
addition, the quantitative insulin sensitivity check index (QUICKI) was
calculated (19).
Sexual and prostate function
Subjects completed a sexual function questionnaire (12), including
questions about the frequency of morning erections and the ability to
maintain an erection, and the Beck Depression Inventory questionnaire
(20), including a question concerning loss of interest in sex. Prostate
functionwas assessed bymeasurements of serum PSA and completion of
the International Prostate Symptom Score (IPSS) questionnaire (21).
Statistical analyses
In the analysis, outcomes such as hormone levels, QUS parameters,
and PSA/IPSS levels were treated as continuous variables. Sexual dys-
function measures were dichotomized: poor morning erection was de-
fined as the frequency of morning erections in the last 4 wk: none/less
than one per month vs. two to three per month or more. Erectile dys-
function was defined as the ability to reach and keep an erection good
enough for sexual intercourse in the last 4 wk: never/sometimes vs. usu-
ally/always (12). Poor libido was defined as loss of interest in sex in the
last 4 wk: completely/much less interested vs. less interested/no change.
AR CAG repeat length was treated as a continuous variable.
Descriptive statistics were used to characterize the distribution of
CAGrepeat length by age and center. The association between endocrine
and anthropometric, bone, IPPS, and PSA measures and repeat length
was assessed initially using scatter plots, superimposing linear lines and
lowess (LOcally-WEighted Scatter plot Smooth) curves (22). Linear re-
gression was then used to determine the association between each of the
endocrine factors and repeat length, with the endocrine factors as the
dependent variables. The results are expressed as absolute differences
( coefficients) and 95% confidence intervals (CI). Logistic regression
was used to determine the association between the sexual dysfunction
categories and repeat length, with results expressed as odd ratios and
95%CI compared with a reference (usually no orminimal dysfunction).
Adjustments were made for age and center, calculating corrected SE val-
ues to account for differences between centers. Statistical analysis was
performed using STATA version 9.2 (http://www.stata.com). All the
statistically significant associations remained significant after exclusion
of outliers in CAG length.
Results
AR CAG repeat lengths in the European populations
The characteristics of the 2878 men included in the analysis
are shown in Table 1. Themean ( SD) repeat lengthwas 22.1
3.1. There were some small, albeit statistically significant, pop-
ulation differences (n 294–407 per center) (Table 2), the larg-
est, 0.6, being between themeanCAG repeat length ofmen from
Leuven, Belgium (21.8) and Lodz, Poland (22.4) (P  0.05). A
standardized normal probability plot (data not shown) indicated
that the repeat length was normally distributed. There was no
association between repeat length and age (Table 3 and supple-
mental data).
CAG repeat length and circulating T, E2, and SHBG
levels
Men with longer CAG repeat lengths had significantly (P 
0.001) higher levels of total T (Fig. 1A and Table 4), an associ-
ation that persisted after adjustment for age and center ( coef-
ficient0.134nmol/liter; 95%CI, 0.067, 0.201). Similar results
were seen for free and bioavailable T ( coefficient  2.643
pmol/liter; 95% CI, 1.688, 3.598; and  coefficient  0.065
TABLE 1. Characteristics of subjects (n  2878)
Mean (SD) or %
Age (yr) 59.9 (11.1)
Height (m) 1.73 (0.07)
Weight (kg) 83.3 (14.0)
Total T (nmol/liter) 16.5 (5.9)
Free T (pmol/liter) 291.7 (92.5)
Bioavailable T (nmol/liter) 7.0 (2.3)
Total E2 (pmol/liter) 92.5 (29.0)
Free E2 (pmol/liter) 1.6 (0.5)
Bioavailable E2 (pmol/liter) 64.5 (20.8)
FSH (nmol/liter) 8.6 (8.9)
LH (nmol/liter) 6.2 (4.3)
SHBG (nmol/liter) 42.8 (19.7)
PSA (g/liter) 1.9 (4.9)
IPSS (0–35) 5.7 (6.0)
BUA (dB/MHz) 80.1 (18.9)
SOS (m/sec) 1550.5 (33.9)
BMD (g/cm2) 0.54 (0.14)
QUI 97.8 (21.8)
Poor morning erectiona 39.1%
Erectile dysfunctionb 29.9%
Poor libidoc 14.4%
a Poor morning erection is defined as the frequency of morning erections in the
last 4 wk: none/ 1 per month vs. 2–3 per month or more.
b Erectile dysfunction is defined as the ability to get and keep an erection that
would be good enough for sexual intercourse in the last 4 wk: never/sometimes
vs. usually/always.
c Poor libido is defined as loss of interest in sex in the last 2 wk: completely/much
less interested vs. less interested/no change.
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nmol/liter; 95% CI, 0.041, 0.089, respectively). In addition,
therewasapositive linear relationshipbetween repeat lengthand
the product of T  LH, an index reflecting relative androgen
insensitivity ( coefficient  0.802; 95% CI, 0.010, 1.594).
The association between CAG repeat length and E2 was very
similar to that with T, showing a significant (P 0.001) positive
associationbetween total E2 levels and repeat length (Fig. 1Band
Table 4). It persisted after adjustment for age and center ( co-
efficient 0.656 pmol/liter; 95% CI, 0.335, 0.977). Similar re-
sultswere seen for free E2 ( coefficient0.012pmol/liter; 95%
CI, 0.006, 0.018) and bioavailable E2 ( coefficient  0.486
pmol/liter; 95% CI, 0.254, 0.718). As expected, total T and E2
levels showed a clear linear correlation ( coefficient  0.075;
P  0.001) (Fig. 1C). Furthermore, there was no association
betweenCAG length andE2/T ratio ( coefficient 0.001; 95%
CI, 0.039, 0.042), suggesting that the same proportion of T
was aromatized to E2 at the entire range of CAG repeat lengths.
Repeat length was weakly and negatively associated (P 
0.05) with serum FSH levels ( coefficient  0.110 U/liter;
95% CI, 0.207, 0.013) (Table 4). The FSH/LH ratio also
decreasedwith increasing repeat length ( coefficient0.020;
95%CI,0.035,0.004), but therewasno relationshipbetween
LH levels and CAG repeats ( coefficient0.008 U/liter; 95%
CI, 0.056, 0.039). Likewise, SHBG levels were not associated
withCAGrepeat lengths ( coefficient0.004nmol/liter; 95%CI,
0.206, 0.213).
TABLE 3. Parameters in which nonsignificant correlations with
the AR CAR repeat length were found in the study population
Parameter  coefficient 95% CI
Age 0.001 yr 0.011, 0.009
Height 0.064 cm 0.139, 0.010
Weight 0.054 kg 0.209, 0.102
Waist circumference 0.031 cm 0.093, 0.155
Waist/hip ratio 0.000 0.001, 0.001
% Body fat 0.000 0.000, 0.001
Total cholesterol 0.007 mmol/liter 0.020, 0.006
HDL-cholesterol 0.003 mmol/liter 0.001, 0.007
LDL-cholesterol 0.004 mmol/liter 0.015, 0.007
HOMA-IR 0.002 0.038, 0.034
HOMA-S 0.000 0.004, 0.004
HOMA-B 0.093 1.157, 0.970
QUICKI 0.000 0.001, 0.001
Systolic BP 0.028 mm Hg 0.192, 0.248
Diastolic BP 0.011 mm Hg 0.148, 0.126
Hemoglobin 0.002 g/liter 0.010, 0.014
Platelets 0.221 ( 106/liter) 0.415, 0.856
Red blood cell count 0.002 ( 106/liter) 0.002, 0.007
White blood cell count 0.017 ( 106/liter) 0.036, 0.003
PSA 0.005 g/liter 0.032, 0.042
IPSS prostatic symptoms
questionnaire
0.034 0.100, 0.033
Odds ratio
Poor morning erections 0.989 0.963, 1.016
Erectile dysfunction 0.990 0.960, 1.021
Poor libido 0.995 0.959, 1.033
BP, Blood pressure.
TABLE 2. AR CAG repeat lengths in the different centers of
the EMAS study, in descending order of length
Center n Mean SD Median
Lodz 393 22.4 3.3 22
Florence 407 22.3 3.0 22
Tartu 294 22.3 3.0 22
Szeged 383 22.2 3.3 22
Malmö 308 22.0 3.2 22
Santiago 369 22.0 3.1 21
Manchester 370 21.9 3.0 21
Leuven 354 21.8 3.0 21
Overall 2878 22.1 3.1 22
FIG. 1. Influence of AR CAG repeat length on total T (A) and E2 (B) levels, and
the correlation of serum T and E2 levels (C). The solid lines represent the
continuous relationship, the dashed lines represent locally weighted scatterplot
smoothing (lowess).  coeff is the coefficient from linear regression.
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CAG length and anthropometric parameters
There was no association between repeat length and any of
the anthropometric measures, including height, weight, waist
circumference, waist/hip ratio, and percentage of body fat
(Table 3).
CAG length and QUS parameters
Repeat length was positively associated with ultrasound pa-
rameters at the calcaneus (Table 4). Increasing repeat lengthwas
significantly associated with increasing SOS ( coefficient 
0.420m/sec; 95%CI, 0.037, 0.803) and the derived parameters,
QUS-estimated bone density ( coefficient 0.002 g/cm2; 95%
CI, 0.000, 0.003) and QUI ( coefficient  0.279; 95% CI,
0.029, 0.528). There was, however, no association with BUA
( coefficient  0.123 dB/MHz; 95% CI, 0.093, 0.339).
The associations between CAG length and the QUS param-
eters became slightly weaker and nonsignificant after further
adjustment for E2: SOS ( coefficient  0.332 m/sec; 95% CI,
0.051, 0.716; P  0.09), QUS-estimated bone density ( co-
efficient  0.001 g/cm2; 95% CI, 0.0002, 0.003; P  0.08),
QUI ( coefficient 0.217; 95%CI,0.033, 0.466; P 0.09),
and BUA ( coefficient  0.072 dB/MHz; 95% CI, 0.144,
0.288; P  0.52).
CAG length and metabolic, cardiovascular, and
hematological parameters
With respect to blood lipids, aweaknegative association (P
0.05) was found between CAG length and triglycerides ( coef-
ficient0.015mmol/liter; 95%CI,0.027,0.003), but no
associations were observed with total cholesterol, HDL-choles-
terol, or LDL-cholesterol. There were no associations with the
measures of insulin sensitivity/resistance, as monitored by
HOMA-IR, HOMA-S, HOMA-B, or QUICKI. Similarly, there
was no correlation between CAG repeat length and systolic or
diastolic blood pressure, nor did we find associations between
CAG repeat length and the hematological parameters, including
hemoglobin, and platelet and red and white blood cell counts
(Table 3). BMI did not influence the relationships between CAG
length and plasma lipids, blood pressure, or measures of insulin
resistance (results not shown). Hence, BMI would be unlikely to
confound any of the other relationships we have presented.
CAG length and measures of sexual and prostatic
function
There was no difference in repeat lengths between men with
andwithout sexual dysfunctionasdefinedbypoormorning erec-
tion, erectile dysfunction, and poor libido. Similarly, there was
no association between repeat length and serumPSA levels or the
IPSS prostatic symptoms questionnaire (Table 3).
Discussion
We present here the largest dataset to date of AR CAG repeat
measurements from a group of 2878 Europeanmen aged 40–79
yr. Themean repeat lengthmeasured, 22.13.1 (SD), is in agree-
ment with previous data on Caucasian populations (1, 23). The
availability of extensive clinical and laboratory data allowed
detailed and robust genotype/phenotype correlations on the pu-
tative effects of this genetic polymorphism of androgen action.
Some clear conclusions could be made: 1) The AR CAG repeat
length correlated directly with all measures (total, bioavailable,
free) of serum T and E2, and there was a strong positive corre-
lation between circulating levels of T and E2. 2) Because the
transcriptional activity of AR decreases with increasing CAG
repeat length (1), a parallel increase in molar concentrations of
E2 and T levels implies a concomitant increase in the ratio of
estrogen/androgen bioactivity (discussed below). 3) The CAG
length correlated positively with calcaneal QUS-estimated bone
density and inversely with FSH and FSH/LH ratio (discussed
below), lending support to heightened estrogen action in themen
with longer repeats. 4) No symptoms or signs suggestive of an-
drogen deficiency were found to correlate with CAG repeat
length. Hence, our data suggest that the concomitant increase of
circulating T levels in men with longer repeats can adequately
compensate for the lower AR activity to prevent apparent defi-
ciency of androgen action. Instead, signs of the simultaneously
elevated estrogen action can be detected in the form of increased
calcaneal ultrasound parameters and reduced FSH/LH ratio. All
expected correlations of CAG repeat length with estrogenicity
(e.g. SHBG and HDL-cholesterol) did not reach significance,
apparently due to the mild nature of associations.
Many publications indicate inverse relations between the re-
peat length and androgen-dependent clinical endpoints (1). For
example, direct correlationof the repeat lengthhasbeen reported
with HDL-cholesterol and flow-mediated arterial dilatation (5,
TABLE 4. Influence of CAG repeat length on sex hormones,
gonadotropins, SHBG, and calcaneal ultrasound parameters
Dependent variables
Independent variable: CAG repeat
length (6–39 repeats)
 coefficient (95% CI) P value
Sex hormones
Total T (nmol/liter) 0.134 (0.067, 0.201) 0.001
Free T (pmol/liter) 2.643 (1.688, 3.598) 0.001
Bioavailable T (nmol/liter) 0.065 (0.041, 0.089) 0.001
T  LH product 0.802 (0.010, 1.594) 0.047
Total E2 (pmol/liter) 0.656 (0.335, 0.977) 0.001
Free E2 (pmol/liter) 0.012 (0.006, 0.018) 0.001
Bioavailable E2 (pmol/
liter)
0.486 (0.254, 0.718) 0.001
E2/T ratio 0.001 (0.039, 0.042) 0.95
Gonadotropins and SHBG
FSH (nmol/liter) 0.110 (0.207, 0.013) 0.03
LH (nmol/liter) 0.008 (0.056, 0.039) 0.73
FSH / LH ratio 0.020 (0.035, 0.004) 0.01
SHBG (nmol/liter) 0.004 (0.206, 0.213) 0.97
Calcaneal ultrasound
QUS-estimated bone
density (g/cm2)
0.002 (0.000, 0.003) 0.02
BUA (db/Mhz) 0.123 (0.093, 0.339) 0.26
SOS (m/s) 0.420 (0.037, 0.803) 0.03
QUI 0.279 (0.029, 0.528) 0.03
The sex hormones, gonadotropins, and ultrasound parameters are dependent
variables, and CAG repeat length is the independent variable adjusted for age
and center. For example, total T level increases by 0.134 nmol/liter for every one
unit increase in repeat length.
J Clin Endocrinol Metab, January 2009, 94(1):277–284 jcem.endojournals.org 281
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 09 February 2015. at 01:56 For personal use only. No other uses without permission. . All rights reserved.
24), as well as body fat, insulin, and leptin (25). Inverse corre-
lations have also been detected with acne and male-type balding
(26, 27), sperm counts (28, 29), BMD (30), as well as prostate
size and the serumPSA level (31,32).However, these findings are
equaled or outnumbered by reports of equivocal, or even oppo-
site associations, as extensively reviewed recently by Rajender
et al. (1). Uncertainty in particular applies to the two most ex-
tensively studied CAG repeat associations, i.e. to male infertility
and prostatic cancer. Thus, although the weaker activity of AR
with longer CAG repeats is well documented, it remains unclear
to what extent the increased androgen levels can compensate for
this. Admittedly, the recent meta-analyses show significant cor-
relation of theCAG repeat lengthwith idiopathicmale infertility
(23) andmarginally inverse associationwith prostate cancer risk
(32). Reasons for the inconsistency of findings include small
numbers of subjects, type of subjects studied (patients vs. general
population), effect of race/ethnicity, and inconsistencies in in-
clusion criteria. EMAS avoids some of these drawbacks with its
large sample size randomly selected from the general population
and its comprehensive and carefully standardized data.
The AR CAG repeat length correlated significantly not only
with the total, free, and bioavailable levels of serum T but also
with E2. Similar T/CAG correlation has been shown in some (2,
3), but not all (4–7, 30), previous reports. Two studies have
shown that the CAG length and T correlate only in oldermen (3,
4), but we found no interaction of age with the positive corre-
lation of T levels and the CAG repeat length. The correlation of
E2 levels with CAG repeats has previously been found to be
inconsistent (2, 5–7).We found that theT andE2 concentrations
were highly correlated, and hence the E2/T ratio remained con-
stant as the CAG repeat length increased. In this sense, the long
CAG repeat with increased E2 production resembles mild forms
of androgen insensitivity syndrome (33, 34). Because androgen
action is relatively impaired but estrogen action is maintained,
when the CAG repeats become longer, the effective bioactive
estrogen/androgen ratio must increase. We may therefore ques-
tion whether any of the reported phenotypic effects of the CAG
repeat length are actually due to differences in androgen, but
rather in estrogen action. We do not dispute the weaker activity
of the AR with long CAG repeats because increasing repeat
length significantly associated with elevated T LH product, as
an index of lower androgen sensitivity (2, 33, 34).
The CAG/phenotype correlates can be classified into purely
androgenic (such as libido, muscle mass), predominately estro-
genic (e.g.BMD), and thosewith opposite effects of estrogen and
androgen (e.g. spermatogenesis). We did not find any evidence
for an inverse relationship of CAG repeat length and the level of
androgen action, i.e. sexual function, body composition, blood
lipids, insulin sensitivity, and hemoglobin. In contrast, therewas
a significant positive correlation with calcaneal ultrasound pa-
rameters, which likely reflects action of the increased E2 levels.
Likewise, the suppressed FSH levels in the face of unaltered LH
can be considered to represent a relative increase in estrogen
action, known to mediate the negative feedback action of ste-
roids on FSH secretion (35). In contrast, both direct actions of
estrogen and androgen participate in the feedback regulation of
LH, and in the absence of enhanced androgen actionwith longer
CAG repeats the enhanced estrogen action may have been in-
sufficient to achieve significant suppression of LH secretion.
Moreover, the documented effects ofCAGrepeat length on sper-
matogenesis and prostate cancer risk may reflect differences in
the E2/T ratio. Estrogens have direct inhibitory effects on tes-
ticularLeydig cell function (36) and spermatogenesis (37),which
may explain why men with longer CAG repeats have higher
frequency of idiopathic infertility. The role of estrogens in the
putative connectionbetween theCAGrepeat length andprostate
cancer seems less clear because the majority of findings suggest
positive associations between estrogen and prostate cancer (38).
Data on effects ofARCAG repeat length on BMDofmen are
confusing. Although most studies show no association in
younger or older men (6, 39–41) (n 91–273), one large study
(n  611) demonstrates a direct correlation between the repeat
length and dual-energy x-ray absorptiometry BMD in lumbar
spine, femoral neck, and total hip (42), and one small study (n
110), using the less well-validated end-point of finger ultra-
sound, shows negative correlation (30). We have shown that
ultrasound parameters of the calcaneus correlate positively with
the CAG repeat length. Because we also showed positive correla-
tion between CAG repeats with E2, our findings suggest that the
elevated estrogen levels in men with longer repeats may lead to
higher bone ultrasound parameters. Accordingly, significance of
the CAG repeat/BMD correlation was lost when adjusted for E2.
Why only one previous study has shown similar positive cor-
relation while most others showed none or a negative relation-
ship is unclear and may reflect the small sample sizes and dif-
ferences in bone measurements. Given that variations in AR
CAG repeats are intrinsically compensated by an intact hypo-
thalamic-pituitary-testicular axis and do not generally result in
overt relative androgen deficiency, it is likely that any differences
are subtle and detectable only when large populations are
analyzed.
Previous studies have observed that CAG repeat length cor-
relates negatively with BMI (43) or positively with fat free mass
(4) andHDL-cholesterol (5, 24). However, also discrepant find-
ings exist, showing positive correlation of CAG lengthwith BMI
or body fat content (7, 25). Amore complicated relationshipwas
found in another study,where unfavorable effects of lowT levels
on body composition were stronger among men with longer
CAG repeats (44).We found no relationship with anthropomet-
ric measures, and the CAG/hormone relationships were similar
in obese and nonobese men. The only significant correlation in
these parameters found in the present study was the inverse cor-
relation of CAG repeat length with triglycerides.
A similar confusion seems to prevail in cardiovascular end-
points. Men with shorter repeats have been found in one study
to have more severe coronary artery disease (7), but another
studydidnot confirm this (24).A recent longitudinal report from
the Massachusetts Male Aging Study showed no relationship
between the CAG repeat length and BMI, HDL-cholesterol,
LDL-cholesterol, waist-to-hip ratio, or the prevalence of coro-
nary heart disease (45). Further confusion is added by the un-
confirmed finding that the CAG length correlates directly with
HDL-cholesterol and flow-mediated vasodilation (5), especially
because the same authors subsequently reported direct correla-
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tion of CAG with high BMI (25). Our findings did not support
association of the CAG repeat with variables considered predic-
tive of cardiovascular diseases. Neither did the repeat length
correlatewithage, suggesting that its effect onhealth statusof the
men was not large enough to affect mortality.
Although all laboratories in the EMAS centers (all major uni-
versity hospitals) employed internationally standardized meth-
odologies and subscribed to external quality assurance scheme
monitoring, it is acknowledged that the possibility of small in-
terlaboratory differences in biochemistry results cannot be com-
pletely excluded. We only assessed phenotypic correlations of
oneAR polymorphism in this study, and other alterations of AR
structure and function are likely to have additional phenotypic
effects.
Taken together,menwith longerARCAG repeats had higher
T levels, which could compensate partly or totally for theweaker
activity of their AR. This is a highly plausible explanation for the
lack of any clear signs of androgen deficiency in the EMAS men
with longer CAG repeats. A potentially more important finding
was the higher E2 levels in men with longer repeats, which par-
alleled with phenotypic effects indicative of elevated estrogen
action. Hence, our current findings suggest that the increased
estrogen action and increased estrogen/androgen ratio in asso-
ciation with longer AR CAG repeats is paradoxically the main
determinant of phenotypic effects of this polymorphism, rather
than an androgen-AR effect.
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